Benzinga | Dec 6, 2021 07:18AM EST

Adicet Bio Announces Positive Interim Clinical Data From First-Ever Allogeneic, Off-The-Shelf, Gamma Delta CAR T Investigational Cell Therapy

* Complete and near complete responses observed with ADI-001 starting at lowest dose level in Phase 1 study for the treatment of B-cell Non-Hodgkin's Lymphoma (ORR=75%, CR=50%)

* No ADI-001-related serious adverse events, including GvHD, neurotoxicity or high-grade CRS have been reported to date

* Evidence of in vivo expansion and circulating pharmacodynamic biomarkers consistent with ADI-001 activation

* Favorable safety and clinical activity reinforces the potential of Adicet's first-in-class allogeneic, off-the-shelf gamma delta CAR T cell platform

* Company to hold webcast today at 5:30am PT / 8:30am ET